Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 107

Similar articles for PubMed (Select 22717018)

1.

Escitalopram reduces attentional performance in anxious older adults with high-expression genetic variants at serotonin 2A and 1B receptors.

Lenze EJ, Dixon D, Nowotny P, Lotrich FE, Doré PM, Pollock BG, Hinrichs AL, Butters MA.

Int J Neuropsychopharmacol. 2013 Mar;16(2):279-88. doi: 10.1017/S1461145712000351. Epub 2012 Apr 17.

2.

Common selective serotonin reuptake inhibitor side effects in older adults associated with genetic polymorphisms in the serotonin transporter and receptors: data from a randomized controlled trial.

Garfield LD, Dixon D, Nowotny P, Lotrich FE, Pollock BG, Kristjansson SD, Doré PM, Lenze EJ.

Am J Geriatr Psychiatry. 2014 Oct;22(10):971-9. doi: 10.1016/j.jagp.2013.07.003. Epub 2013 Sep 8.

PMID:
24021217
3.

Relation of serotonin transporter genetic variation to efficacy of escitalopram for generalized anxiety disorder in older adults.

Lenze EJ, Goate AM, Nowotny P, Dixon D, Shi P, Bies RR, Lotrich FK, Rollman BL, Shear MK, Thompson PA, Andreescu C, Pollock BG.

J Clin Psychopharmacol. 2010 Dec;30(6):672-7.

4.

The role of 5-HT1a and 5-HT2a receptors in attention and motor control: a mechanistic study in healthy volunteers.

Wingen M, Kuypers KP, Ramaekers JG.

Psychopharmacology (Berl). 2007 Feb;190(3):391-400. Epub 2006 Nov 24.

PMID:
17124621
5.

Elevated cortisol in older adults with generalized anxiety disorder is reduced by treatment: a placebo-controlled evaluation of escitalopram.

Lenze EJ, Mantella RC, Shi P, Goate AM, Nowotny P, Butters MA, Andreescu C, Thompson PA, Rollman BL.

Am J Geriatr Psychiatry. 2011 May;19(5):482-90. doi: 10.1097/JGP.0b013e3181ec806c.

6.

Female sexual dysfunction in patients with major depressive disorder (MDD) treated with selective serotonin reuptake inhibitor (SSRI) and its association with serotonin 2A-1438 G/A single nucleotide polymorphisms.

Masiran R, Sidi H, Mohamed Z, Mohd Nazree NE, Nik Jaafar NR, Midin M, Das S, Mohamed Saini S.

J Sex Med. 2014 Apr;11(4):1047-55. doi: 10.1111/jsm.12452. Epub 2014 Feb 18.

PMID:
24533444
7.

Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder.

Foster RH, Goa KL.

CNS Drugs. 1997 Aug;8(2):163-88. doi: 10.2165/00023210-199708020-00010.

PMID:
23338224
8.

Escitalopram for older adults with generalized anxiety disorder: a randomized controlled trial.

Lenze EJ, Rollman BL, Shear MK, Dew MA, Pollock BG, Ciliberti C, Costantino M, Snyder S, Shi P, Spitznagel E, Andreescu C, Butters MA, Reynolds CF 3rd.

JAMA. 2009 Jan 21;301(3):295-303. doi: 10.1001/jama.2008.977.

9.

Genetic variation in the serotonin transporter and HTR1B receptor predicts reduced bone formation during serotonin reuptake inhibitor treatment in older adults.

Garfield LD, Müller DJ, Kennedy JL, Mulsant BH, Reynolds CF 3rd, Teitelbaum SL, Civitelli R, Dixon D, Todorov AA, Lenze EJ.

World J Biol Psychiatry. 2014 Jul;15(5):404-10. doi: 10.3109/15622975.2013.832380. Epub 2013 Sep 30.

10.

Characterization of 5-HT(1A/1B)-/- mice: an animal model sensitive to anxiolytic treatments.

Guilloux JP, David DJ, Xia L, Nguyen HT, Rainer Q, Guiard BP, Repérant C, Deltheil T, Toth M, Hen R, Gardier AM.

Neuropharmacology. 2011 Sep;61(3):478-88. doi: 10.1016/j.neuropharm.2011.02.009. Epub 2011 Feb 17.

PMID:
21333660
11.

Short-term serotonergic but not noradrenergic antidepressant administration reduces attentional vigilance to threat in healthy volunteers.

Murphy SE, Yiend J, Lester KJ, Cowen PJ, Harmer CJ.

Int J Neuropsychopharmacol. 2009 Mar;12(2):169-79. doi: 10.1017/S1461145708009164. Epub 2008 Aug 28.

PMID:
18752726
13.

[Efficacy and tolerability of escitalopram in anxiety disorders: a review].

Pelissolo A.

Encephale. 2008 Sep;34(4):400-8. doi: 10.1016/j.encep.2008.04.004. Epub 2008 Aug 15. Review. French.

PMID:
18922243
14.

SSRI response in depression may be influenced by SNPs in HTR1B and HTR1A.

Villafuerte SM, Vallabhaneni K, Sliwerska E, McMahon FJ, Young EA, Burmeister M.

Psychiatr Genet. 2009 Dec;19(6):281-91. doi: 10.1097/YPG.0b013e32832a506e.

15.

Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial.

Stahl SM, Gergel I, Li D.

J Clin Psychiatry. 2003 Nov;64(11):1322-7.

PMID:
14658946
16.

[Mechanisms of action of antidepressants: new data from Escitalopram].

Fabre V, Hamon M.

Encephale. 2003 May-Jun;29(3 Pt 1):259-65. French.

PMID:
12876551
17.

Selective verbal and spatial memory impairment after 5-HT1A and 5-HT2A receptor blockade in healthy volunteers pre-treated with an SSRI.

Wingen M, Kuypers KP, Ramaekers JG.

J Psychopharmacol. 2007 Jul;21(5):477-85. Epub 2006 Nov 8.

PMID:
17092965
18.

Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study.

Davidson JR, Bose A, Korotzer A, Zheng H.

Depress Anxiety. 2004;19(4):234-40.

PMID:
15274172
19.

Association between 5HT2A polymorphism and selective serotonin re-uptake inhibitor (SSRI)-induced sexual desire disorder (SDD) among Malaysian women.

Masiran R, Sidi H, Mohamed Z, Mohamed Saini S, Nik Jaafar NR.

Asia Pac Psychiatry. 2013 Apr;5 Suppl 1:41-9. doi: 10.1111/appy.12043.

PMID:
23857836
20.

SSRI effects on pyschomotor performance: assessment of citalopram and escitalopram on normal subjects.

Paul MA, Gray GW, Love RJ, Lange M.

Aviat Space Environ Med. 2007 Jul;78(7):693-7.

PMID:
17679567
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk